Atherosclerosis
Volume 204, Issue 2 , Pages 601-607 , June 2009

Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study

  • Renate Schnabel

      Affiliations

    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
    • ,
  • Josée Dupuis

      Affiliations

    • Department of Biostatistics, Boston University, School of Public Health, Boston, MA, United States
    • ,
  • Martin G. Larson

      Affiliations

    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
    • Boston University’s Mathematics and Statistics Department, Boston, MA, United States
    • ,
  • Kathryn L. Lunetta

      Affiliations

    • Department of Biostatistics, Boston University, School of Public Health, Boston, MA, United States
    • ,
  • Sander J. Robins

      Affiliations

    • Department of Preventive Medicine, Boston University, School of Medicine, Boston, MA, United States
    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
    • ,
  • Yanyan Zhu

      Affiliations

    • Department of Biostatistics, Boston University, School of Public Health, Boston, MA, United States
    • ,
  • Jian Rong

      Affiliations

    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
    • ,
  • Xiaoyan Yin

      Affiliations

    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
    • ,
  • Heide A. Stirnadel

      Affiliations

    • Cardiovascular, Metabolic and Genetic Support, GlaxoSmithKline R&D, Harlow, UK
    • ,
  • Jeanne J. Nelson

      Affiliations

    • Cardiovascular, Metabolic and Genetic Support, GlaxoSmithKline R&D, Harlow, UK
    • ,
  • Peter W.F. Wilson

      Affiliations

    • Department of Medicine, Division of Cardiology, Emory University, School of Medicine, Harlow, UK
    • ,
  • John F. Keaney
    • ,
  • Ramachandran S. Vasan

      Affiliations

    • Evans Memorial Department of Medicine, Boston University, School of Medicine, Boston, MA, United States
    • Whitaker Cardiovascular Institute, Boston University, School of Medicine, Boston, MA, United States
    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
    • ,
  • Emelia J. Benjamin

      Affiliations

    • Evans Memorial Department of Medicine, Boston University, School of Medicine, Boston, MA, United States
    • Whitaker Cardiovascular Institute, Boston University, School of Medicine, Boston, MA, United States
    • Department of Epidemiology, Boston University, School of Public Health, Boston, MA, United States
    • The NHLBI’s Framingham Heart Study, Framingham, MA, United States
    • Corresponding Author InformationCorresponding author at: Boston University, The Framingham Heart Study, 73 Mount Wayte Avenue, Suite 2, Framingham, MA 01702-5827, United States. Tel.: +1 617 638 8968; fax: +1 508 626 1262.

Received 1 July 2008 ,Revised 15 October 2008 ,Accepted 16 October 2008.

Reference 

  1. Lavi S, McConnell JP, Rihal CS, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007;115:2715–2721
  2. Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148–55.
  3. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26:1586–1593
  4. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837–842
  5. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302–1306
  6. Daniels LB, Laughlin GA, Sarno MJ, et al. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol. 2008;51:913–919
  7. Ninio E, Tregouet D, Carrier JL, et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet. 2004;13:1341–1351
  8. Abuzeid AM, Hawe E, Humphries SE, Talmud PJ. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis. 2003;168:283–288
  9. Tang HK, Siegmund D. Mapping quantitative trait loci in oligogenic models. Biostatistics. 2001;2:147–162
  10. Brilakis ES, McConnell JP, Lennon RJ, et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:37–44
  11. Zhang SY, Shibata H, Karino K, et al. Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population. Hypertens Res. 2007;30:403–409
  12. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis. 2007;190:388–396
  13. Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the cardiovascular health study. J Am Geriatr Soc. 2008;56(5):792–799
  14. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007;27:2236–2243
  15. Oei HH, van dM I, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570–575
  16. O’Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. Circulation. 2006;113:1745–1752
  17. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27:1411–1416
  18. Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413–419
  19. Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51:2264–2273
  20. Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007;82:159–165
  21. Guerra R, Zhao B, Mooser V, et al. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res. 1997;38:2281–2288
  22. Diego VP, Rainwater DL, Wang XL, et al. Genotype×adiposity interaction linkage analyses reveal a locus on chromosome 1 for lipoprotein-associated phospholipase A2, a marker of inflammation and oxidative stress. Am J Hum Genet. 2007;80:168–177
  23. Liu PY, Li YH, Wu HL, et al. Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. J Thromb Haemost. 2006;4:1023–1028
  24. Kruse S, Mao XQ, Heinzmann A, et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet. 2000;66:1522–1530
  25. Wang L, Fan C, Topol SE, Topol EJ, Wang Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003;302:1578–1581
  26. Su JL, Yen CJ, Chen PS, et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 2007;96:541–545
  27. Cha HS, Bae EK, Koh JH, et al. Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes. J Rheumatol. 2007;34:16–19
  28. Shin HY, Smith ML, Toy KJ, Williams PM, Bizios R, Gerritsen ME. VEGF-C mediates cyclic pressure-induced endothelial cell proliferation. Physiol Genomics. 2002;11:245–251

☆ Supported by NIH/NHLBI contract N01-HC-25195 and NIH grants HL64753 and HL076784 AG028321 (E.J.B.), HL70139 (R.S.V). NIH Research career award HL04334 (R.S.V.), NIH grant HG000848 (J.D.); Deutsche Forschungsgemeinschaft (German Research Foundation) Research Fellowship SCHN 1149/1-1 (RS). Portion of these analyses were conducted using the Boston University Linux Cluster for Genetic Analysis (LinGA) funded by the NIH NCRR (National Center for Research Resources) Shared Instrumentation grant (1S10RR163736-01A1).

PII: S0021-9150(08)00756-9

doi: 10.1016/j.atherosclerosis.2008.10.030

Atherosclerosis
Volume 204, Issue 2 , Pages 601-607 , June 2009

Article Tools

* Image Usage & Resolution